Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

Graft versus host disease (GvHD) is a complication from stem cell transplants where the patient recognises the cells as ...

A T-cell therapy developed by Orca Bio, a private biotech company, significantly reduced the risk of a debilitating immune ...

Malabar Cancer Centre (MCC) in Kannur successfully implements CAR T-cell therapy, a groundbreaking treatment for blood cancer ...

Results showed Orca’s treatment, a purified mix of donor-derived T cells and stem cells, was safer than standard transplant ...

Cellares, the first Integrated Development and Manufacturing Organization (IDMO), has concluded the Technology Adoption ...

In an interview with Arthur Stril, chief business officer and interim CFO at Cellectis, we explore how gene editing and ...

Oncologists are increasingly favoring CAR T-cell therapy’s early-line use in relapsed/refractory multiple myeloma despite challenges like cost and access.

Treatment with the T-cell immunotherapy Orca-T improved survival free of moderate-to-severe chronic graft-versus-host disease ...

In a real-world study, researchers found this data by comparing treatment patterns, healthcare resource utilization, and ...

T-cell lymphoma is a rare cancer that affects the lymphatic system. Learn about the types, signs, symptoms, treatments, and ...

The Car-T cell therapy was tested on patients with B-cell leukaemia and lymphoma - rare types of blood cancers - that affect the bone marrow and the lymphatic system.